The results indicated that the treatment regimen using B7-H3-targeted CAR T cells (SCRI-CARB7H3(s)) was feasible for CNS tumor patients aged 1–26 years, with subjects tolerating doses of CAR T cells ranging from 1×10^7 to 10×10^7 cells. The gene discussed is CD276; the disease is central nervous system neoplasm.